GET DAILY SIGNALSProKidney (PROK): Following Clinical Milestones for Rilparencel in CKD
Key Takeaways
- ProKidney is a late clinical-stage cell therapy company advancing rilparencel, a first-in-class autologous cell therapy for advanced chronic kidney disease (CKD) with type 2 diabetes.
- PROK traded near $1.52 at its most recent close, down roughly 6% over the prior 30 days and essentially flat over the trailing quarter.
- The company completed enrollment for the Phase 3 PROACT 1 accelerated-approval efficacy analysis, with pivotal eGFR slope data expected in the second quarter of 2027.
- ProKidney ended Q2 2026 with $181.6 million in cash and marketable securities, a runway management expects to fund operations into mid-2027.
- Presented new mechanism-of-action data at ASN Kidney Week 2026 and hosted a virtual key opinion leader event focused on rilparencel's clinical potential.
- For additional context on this ticker, review its Price Targets, Earnings, and Forecast pages.
Market Snapshot for PROK
Shares of PROK have moved within a fairly narrow band in recent months, sitting between roughly $1.30 and $2.00 as investors balance clinical advances against the company’s pre-revenue profile. At the latest close near $1.52, the stock had declined about 6% over the past 30 days and remained essentially unchanged from its level three months earlier. This measured trading pattern fits the catalyst-driven profile of a late-stage biotech without a marketed product and with a key data readout still more than a year out. Daily moves have largely reflected broader sentiment in small-cap and development-stage biotechs rather than any single company event.
ProKidney’s Business Focus and Competitive Edge
ProKidney Corp. develops cellular therapies for chronic kidney disease. Its lead candidate, rilparencel (also called REACT), is a patented autologous cell therapy that carries Regenerative Medicine Advanced Therapy designation from the FDA. The treatment uses a patient’s own kidney cells and aims to preserve function and slow progression in advanced CKD accompanied by type 2 diabetes, an area with limited disease-modifying options.
The main study is the Phase 3 REGEN-006 (PROACT 1) trial, a randomized, blinded, sham-controlled trial. The company has aligned with the FDA on annualized eGFR slope as a surrogate endpoint that could support accelerated approval, potentially making rilparencel a first-in-class option. Strengths include a differentiated mechanism, in-house manufacturing in Winston-Salem, North Carolina, and a defined regulatory path. Investors track the name mainly for clinical and regulatory updates.
Recent Developments Shaping the Story
In the second-quarter 2026 update, ProKidney confirmed it had completed enrollment of patients for the PROACT 1 accelerated-approval efficacy analysis. That cohort is expected to include about 320 patients and will assess annualized eGFR slope. Full enrollment of roughly 470 patients for the confirmatory portion remains on schedule for the second half of 2026.
Early in October 2026, eight abstracts, including one oral presentation, were accepted for the American Society of Nephrology Kidney Week 2026. The presentations covered translational models, drug-product characterization, and pooled Phase 2 safety and efficacy data, all supporting a multifactorial mechanism for rilparencel. The company followed up with a virtual key opinion leader event featuring nephrology researcher Katherine Tuttle, M.D. On the balance sheet, ProKidney closed Q2 2026 with $181.6 million in cash, cash equivalents, and marketable securities.
I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
2026 Outlook and Key Items to Monitor
The most important catalysts ahead remain clinical and regulatory milestones. Investors will watch for completion of full PROACT 1 enrollment in the second half of 2026, which leads into the pivotal eGFR slope readout now expected in the second quarter of 2027. Further mechanistic and Phase 2 data releases could strengthen the scientific case, while manufacturing updates and FDA interactions under the RMAT designation will clarify the route to a potential Biologics License Application.
Principal risks include the uncertainty typical of late-stage trials, the possibility that the FDA may require additional studies, and reliance on the cash runway, which management projects will support operations into mid-2027. Sector-wide conditions affecting small-cap biotechnology, such as financing availability and rotation in investor sentiment, could also influence trading. These elements highlight the value of a disciplined, data-focused approach when following the name.
Using AI Tools for Additional Perspective
When reviewing names like PROK, I sometimes look at Tickeron’s AI Trading Bots to see how automated strategies are currently positioned around the stock. The platform offers a range of bots with different timeframes and risk parameters, which can provide another lens on market activity without replacing fundamental analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PROK's RSI Oscillator ascending out of oversold territory
The RSI Indicator for PROK moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In 24 of the 29 cases the stock moved higher. This puts the odds of a move higher at 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +8.27% 3-day Advance, the price is estimated to grow further. Considering data from situations where PROK advanced for three days, in 200 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
PROK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PROK as a result. In 77 of 100 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.
PROK moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for PROK crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 20 of 21 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PROK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for PROK entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 25 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.358) is normal, around the industry mean (3.037). P/E Ratio (-2.755) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (344.828) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. PROK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PROK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement